Kura Oncology, Inc. (KURA) Stock Forecast
KURA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.69 / 5 from 16 analysts
- Price target
- $31.85 average of analyst targets
- Upside to target
- +250.7% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.83
- 52-week range
- $7.40 – $13.59
KURA analyst ratings
16 analystsNumber of analysts at each rating.
KURA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KURA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.99 | −$0.70 | −$0.85 | +5.2% | 10 |
| Current fiscal year (2026) | −$3.17 | −$3.48 | −$2.98 | −$3.18 | +0.2% | 10 |
| Next fiscal year (2027) | −$2.35 | −$3.26 | −$1.58 | −$3.17 | +26.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KURA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $23.8M | $9.2M | $29.1M | +14.8% | 15 |
| Current fiscal year (2026) | $96.1M | $77.5M | $139.4M | +42.5% | 15 |
| Next fiscal year (2027) | $208.4M | $135.6M | $473.0M | +116.8% | 14 |
KURA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KURA revenue: reported and forecast
KURA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.90 | −$0.81 | −$0.81 | −$0.81 | −$0.81 | −10.6% | 7 up · 0 down |
| Current fiscal year (2026) | −$3.46 | −$3.23 | −$3.16 | −$3.17 | −$3.17 | −8.2% | 7 up · 0 down |
| Next fiscal year (2027) | −$2.60 | −$2.30 | −$2.30 | −$2.35 | −$2.35 | −9.6% | 7 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KURA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KURA beat in 6 of 12.
What analysts expect from KURA
16 analysts cover Kura Oncology; their consensus rating is strong buy (4.69 on a 1–5 scale, where 5 is a strong buy). The average price target is $31.85, 250.7% above the latest close of $9.08. Analysts expect earnings of −$3.17 per share for 2026, +0.2% from a year earlier. For 2027 the average estimate is −$2.35 per share on revenue of $208.4 million. Kura Oncology beat the EPS estimate in 6 of the last 12 quarters.
Related: KURA income statement, KURA key metrics, KURA chart. See the KURA stock overview for the latest quote and news.
KURA forecast FAQ
What is Kura Oncology's price target?
The average analyst price target for Kura Oncology is $31.85, 250.7% above the latest close of $9.08.
Is Kura Oncology a buy, hold or sell?
Of 16 analysts covering Kura Oncology, 12 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kura Oncology's EPS forecast?
Analysts forecast −$3.17 per share for 2026 (range −$3.48 to −$2.98); for 2027 the estimate is −$2.35.
What is Kura Oncology's revenue forecast?
The average revenue estimate for 2026 is $96.1 million, growth of 42.5%; for 2027 it is $208.4 million.
When does Kura Oncology report earnings?
Kura Oncology is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-0.83.
Does Kura Oncology usually beat earnings estimates?
Kura Oncology reported EPS at or above the analyst estimate in 6 of the last 12 quarters.